FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308683313> ?p ?o ?g. }

• W4308683313 endingPage "254" @default.
• W4308683313 startingPage "245" @default.
• W4308683313 abstract "Abstract Background Epidermal growth factor receptor (EGFR) is a therapeutic target to which HER2/HER3 activation may contribute resistance. This Phase I/II study examined the toxicity and efficacy of high-dose pulsed AZD8931, an EGFR/HER2/HER3 inhibitor, combined with chemotherapy, in metastatic colorectal cancer (CRC). Methods Treatment-naive patients received 4-day pulses of AZD8931 with irinotecan/5-FU (FOLFIRI) in a Phase I/II single-arm trial. Primary endpoint for Phase I was dose limiting toxicity (DLT); for Phase II best overall response. Samples were analysed for pharmacokinetics, EGFR dimers in circulating exosomes and Comet assay quantitating DNA damage. Results Eighteen patients received FOLFIRI and AZD8931. At 160 mg bd, 1 patient experienced G3 DLT; 160 mg bd was used for cohort expansion. No grade 5 adverse events (AE) reported. Seven (39%) and 1 (6%) patients experienced grade 3 and grade 4 AEs, respectively. Of 12 patients receiving 160 mg bd, best overall response rate was 25%, median PFS and OS were 8.7 and 21.2 months, respectively. A reduction in circulating HER2/3 dimer in the two responding patients after 12 weeks treatment was observed. Conclusions The combination of pulsed high-dose AZD8931 with FOLFIRI has acceptable toxicity. Further studies of TKI sequencing may establish a role for pulsed use of such agents rather than continuous exposure. Trial registration number ClinicalTrials.gov number: NCT01862003." @default.
• W4308683313 created "2022-11-14" @default.
• W4308683313 creator A5008235366 @default.
• W4308683313 creator A5012486076 @default.
• W4308683313 creator A5035078656 @default.
• W4308683313 creator A5040081800 @default.
• W4308683313 creator A5040495838 @default.
• W4308683313 creator A5040991512 @default.
• W4308683313 creator A5047642730 @default.
• W4308683313 creator A5055669649 @default.
• W4308683313 creator A5057992394 @default.
• W4308683313 creator A5062167352 @default.
• W4308683313 creator A5063305665 @default.
• W4308683313 creator A5067711058 @default.
• W4308683313 creator A5083120377 @default.
• W4308683313 creator A5085123244 @default.
• W4308683313 creator A5089670001 @default.
• W4308683313 creator A5090640497 @default.
• W4308683313 date "2022-11-09" @default.
• W4308683313 modified "2023-10-18" @default.
• W4308683313 title "PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer" @default.
• W4308683313 cites W1975274124 @default.
• W4308683313 cites W1980211974 @default.
• W4308683313 cites W1991296878 @default.
• W4308683313 cites W2004439203 @default.
• W4308683313 cites W2011836623 @default.
• W4308683313 cites W2012322739 @default.
• W4308683313 cites W2017081079 @default.
• W4308683313 cites W2031887211 @default.
• W4308683313 cites W2041919461 @default.
• W4308683313 cites W2048286312 @default.
• W4308683313 cites W2069526613 @default.
• W4308683313 cites W2085633477 @default.
• W4308683313 cites W2095201384 @default.
• W4308683313 cites W2099010186 @default.
• W4308683313 cites W2103129141 @default.
• W4308683313 cites W2112570485 @default.
• W4308683313 cites W2120724114 @default.
• W4308683313 cites W2125551363 @default.
• W4308683313 cites W2126474157 @default.
• W4308683313 cites W2129255527 @default.
• W4308683313 cites W2138095640 @default.
• W4308683313 cites W2138267716 @default.
• W4308683313 cites W2145070131 @default.
• W4308683313 cites W2162804910 @default.
• W4308683313 cites W2280920407 @default.
• W4308683313 cites W2403530027 @default.
• W4308683313 cites W2426058879 @default.
• W4308683313 cites W2470575266 @default.
• W4308683313 cites W2559749825 @default.
• W4308683313 cites W2763136348 @default.
• W4308683313 cites W2775605276 @default.
• W4308683313 cites W2990253746 @default.
• W4308683313 cites W2996426997 @default.
• W4308683313 cites W3003259023 @default.
• W4308683313 cites W4237179649 @default.
• W4308683313 doi "https://doi.org/10.1038/s41416-022-02015-x" @default.
• W4308683313 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36352028" @default.
• W4308683313 hasPublicationYear "2022" @default.
• W4308683313 type Work @default.
• W4308683313 citedByCount "2" @default.
• W4308683313 countsByYear W43086833132023 @default.
• W4308683313 crossrefType "journal-article" @default.
• W4308683313 hasAuthorship W4308683313A5008235366 @default.
• W4308683313 hasAuthorship W4308683313A5012486076 @default.
• W4308683313 hasAuthorship W4308683313A5035078656 @default.
• W4308683313 hasAuthorship W4308683313A5040081800 @default.
• W4308683313 hasAuthorship W4308683313A5040495838 @default.
• W4308683313 hasAuthorship W4308683313A5040991512 @default.
• W4308683313 hasAuthorship W4308683313A5047642730 @default.
• W4308683313 hasAuthorship W4308683313A5055669649 @default.
• W4308683313 hasAuthorship W4308683313A5057992394 @default.
• W4308683313 hasAuthorship W4308683313A5062167352 @default.
• W4308683313 hasAuthorship W4308683313A5063305665 @default.
• W4308683313 hasAuthorship W4308683313A5067711058 @default.
• W4308683313 hasAuthorship W4308683313A5083120377 @default.
• W4308683313 hasAuthorship W4308683313A5085123244 @default.
• W4308683313 hasAuthorship W4308683313A5089670001 @default.
• W4308683313 hasAuthorship W4308683313A5090640497 @default.
• W4308683313 hasBestOaLocation W43086833131 @default.
• W4308683313 hasConcept C121608353 @default.
• W4308683313 hasConcept C126322002 @default.
• W4308683313 hasConcept C143998085 @default.
• W4308683313 hasConcept C203092338 @default.
• W4308683313 hasConcept C2776705615 @default.
• W4308683313 hasConcept C2779438470 @default.
• W4308683313 hasConcept C2779998722 @default.
• W4308683313 hasConcept C2780259306 @default.
• W4308683313 hasConcept C2780456651 @default.
• W4308683313 hasConcept C2781187634 @default.
• W4308683313 hasConcept C29730261 @default.
• W4308683313 hasConcept C31760486 @default.
• W4308683313 hasConcept C526805850 @default.
• W4308683313 hasConcept C535046627 @default.
• W4308683313 hasConcept C71924100 @default.
• W4308683313 hasConcept C90924648 @default.
• W4308683313 hasConcept C98274493 @default.
• W4308683313 hasConceptScore W4308683313C121608353 @default.

• next